SEREVENT DISKUS
LABA DPI
Salmeterol xinafoate · GlaxoSmithKline
Active Medication & Mechanism
- Salmeterol xinafoate LABA50 mcg salmeterol per blister
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (≥12 hours) via stimulation of beta2-receptors on airway smooth muscle. Onset is approximately 30–48 minutes.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
1/2 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 50 mcg | Patients ≥4 years | 1 inhalation twice daily (~12 hours apart) For asthma, should only be used as additional therapy in patients NOT adequately controlled on ICS or whose disease warrants ICS + LABA. MUST be used WITH an ICS. | 100 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a rescue inhaler. Onset too slow for acute symptoms. Use a SABA. |
COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 50 mcg | Adults (≥18 years) | 1 inhalation twice daily (~12 hours apart) Maintenance treatment of bronchospasm associated with COPD, including emphysema and chronic bronchitis. | 100 mcg | FDA Approved |
Exercise-Induced Bronchospasm
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 50 mcg | Patients ≥4 years | 1 inhalation at least 30 minutes before exercise Prevention of exercise-induced bronchospasm. Do not use additional doses for 12 hours. | Should not exceed 1 inhalation twice daily | FDA Approved |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |